US Patent 8,883,836: Bendamustine Hydrochloride Form 3 Patent Scope, Claims, and Competitive Landscape

US Patent 8,883,836 protects a specific crystalline form of bendamustine hydrochloride, Form 3, when used in lyophilized injectable products and when produced through a defined lyophilization process. Its strongest commercial coverage is directed to sterile injectable bendamustine products containing Form 3, particularly products using mannitol and tert-butanol and manufactured through the claimed freeze-drying cycle.

The patent does not broadly cover all bendamustine hydrochloride products, all bendamustine formulations, or all treatments for the listed cancers. Its enforceability depends on proving the presence of Form 3, the claimed diffraction profile, the claimed formulation or manufacturing conditions, and, for method claims, administration for a covered indication.

What does US Patent 8,883,836 protect?

The patent contains four principal claim groups:

Claim group	Claims	Protected subject matter
Therapeutic-use claims	1-12	Treating specified cancers with a solution prepared from a lyophilized composition containing bendamustine hydrochloride Form 3
Manufacturing claims	13-18	Producing Form 3 by combining bendamustine hydrochloride, mannitol, water and an organic solvent, followed by lyophilization
Composition claim	19	A lyophilized bendamustine composition prepared by the claimed process
Additional therapeutic-use claims	20-22	Treating specified cancers with an injectable preparation made from the claimed lyophilized composition

The core technical limitation is Form 3, identified by an X-ray powder diffraction pattern containing reflections at approximately 7.9, 15.5 and 26.1 degrees 2θ, each within the stated ±0.2-degree range.

The claims also identify optional or cumulative formulation features:

Additional reflections at approximately 10.6, 19.7 and 23.3 degrees 2θ.
A composition substantially free of other crystalline bendamustine hydrochloride forms.
Amorphous bendamustine hydrochloride.
Pharmaceutically acceptable excipients.
Mannitol as a preferred excipient.
An organic solvent.
tert-Butanol as a preferred solvent.
A bendamustine-to-mannitol ratio of 15:25.5.
A specified lyophilization cycle.

How should the independent claims be construed?

Claim 1: Form 3 in a cancer-treatment method

Claim 1 requires all of the following:

A patient in need of treatment.
One of five listed diseases:
- Chronic lymphocytic leukemia.
- Hodgkin's disease.
- Non-Hodgkin's lymphoma.
- Multiple myeloma.
- Breast cancer.
Administration of a solution.
The solution must be prepared from a lyophilized composition.
The lyophilized composition must contain crystalline bendamustine hydrochloride Form 3.
Form 3 must satisfy the specified powder-diffraction profile.

The claim is narrower than a conventional bendamustine method-of-treatment claim. It does not cover treatment with bendamustine generally. It requires a particular solid-state form in a particular product presentation.

A product containing only amorphous bendamustine, Form 1, Form 2, or another polymorph would fall outside claim 1 if Form 3 is absent. A product containing Form 3 together with other forms could still fall within claim 1 unless the asserted claim also requires the "substantially free" limitation in claim 5.

Claim 13: Form 3 manufacturing process

Claim 13 requires:

Bendamustine hydrochloride.
Mannitol.
Water.
An organic solvent.
Formation of a solution.
Lyophilization of that solution.
Production of Form 3 with the specified diffraction pattern.

This claim is important because it reaches the manufacturing process rather than merely the final therapeutic use. A manufacturer can face process-claim exposure even when its commercial label does not identify the polymorphic form.

The claim does not require tert-butanol. That solvent is added by dependent claim 16. The broader claim 13 therefore covers the listed organic-solvent alternatives if the remaining limitations are met.

Claim 19: Product-by-process composition claim

Claim 19 covers a lyophilized bendamustine composition "prepared according to the method of claim 13." The claim incorporates the process limitations through its reference to claim 13.

In U.S. patent litigation, product-by-process claims are generally analyzed principally by the characteristics of the product, although the manufacturing language remains relevant to claim scope and infringement analysis. The practical issue is whether the accused lyophilized product has the claimed Form 3 characteristics and whether it was made through a process meeting the incorporated limitations. See Federal Circuit precedent on product-by-process claim construction, including Abbott Laboratories v. Sandoz, Inc. [2].

What formulations are protected by US 8,883,836?

The formulation protection is concentrated around a lyophilized injectable product. The claims identify the following formulation architecture:

Feature	Claim status	Commercial significance
Bendamustine hydrochloride Form 3	Required in core claims	Principal solid-state limitation
Lyophilized composition	Required	Targets freeze-dried injectable products
Mannitol	Required in claim 13 and dependent claims; specified ratio in claim 18	Supports cake formation and product stability
Water	Required in claim 13	Starting solvent component
Organic solvent	Required in claim 13	Used in the crystallization/lyophilization process
tert-Butanol	Preferred dependent limitation	Narrows, but strengthens, process coverage
Amorphous bendamustine	Optional in claim 6	Allows mixed solid-state composition
Other crystalline forms excluded	Claim 5	Creates a purer Form 3 embodiment
Defined diffraction reflections	Required	Analytical fingerprint for infringement testing

Claims 7-9 do not limit the formulation to mannitol alone. They list phosphate salts, organic acids, gelatin, glycine, sugars, polyols, dextran, trehalose and related excipients. Claim 9 narrows the excipient to mannitol.

The patent therefore has a layered structure. The broadest commercial zone is a lyophilized injectable composition containing Form 3. Narrower zones cover compositions containing mannitol, tert-butanol, a 15:25.5 ratio, or the specified freeze-drying cycle.

Which technical features create the main infringement risks?

X-ray powder diffraction profile

The strongest objective limitation is the diffraction pattern. A patent owner would typically compare an accused batch against the claimed reflections using powder X-ray diffraction.

The three required reflections are:

Required reflection	Tolerance
7.9 degrees 2θ	±0.2 degrees
15.5 degrees 2θ	±0.2 degrees
26.1 degrees 2θ	±0.2 degrees

Claims 4 and 14 add one or more reflections at 10.6, 19.7 and 23.3 degrees 2θ. Those additional peaks are not required for infringement of claims 1 and 13 unless the particular claim being asserted includes them.

The diffraction limitations create both value and vulnerability. They provide a measurable product definition, but the result can vary with instrument calibration, sample preparation, crystallinity, hydration, preferred orientation and mixed polymorph content. Claim interpretation should therefore address whether each required reflection must be independently detectable and how the ±0.2-degree tolerance applies.

Lyophilization cycle

Claim 17 recites a detailed cycle:

Stage	Claimed condition
Loading	5°C
Freezing	Hold at -50°C for four hours
Primary drying vacuum	150 microns
Primary drying temperature	Hold at -15°C for 27 hours
Intermediate drying	Hold at -12°C for seven hours
Secondary drying vacuum	50 microns
Secondary drying temperature	Hold at 40°C for 15 hours

Claim 17 is narrower than claim 13. A process that uses Form 3, mannitol and tert-butanol but follows a different cycle may still implicate claim 13 or other claims, but would not meet claim 17 solely because it produces Form 3.

When does US Patent 8,883,836 lose exclusivity?

The claims supplied do not state the patent's filing date, priority date, patent-term-adjustment period or terminal disclaimer. Those data control the expiration date and must be taken from the USPTO patent record and the FDA Orange Book listing.

For commercial diligence, the relevant dates are:

Exclusivity category	Relevance
Patent term	Controls enforceable rights under US 8,883,836
Orange Book listing	Determines whether an ANDA applicant must address the patent
New chemical entity exclusivity	Bendamustine's original NCE period is separate from this later crystalline-form patent
Three-year exclusivity	May apply to a later product or indication if statutory requirements were met
Pediatric exclusivity	Can add six months to applicable exclusivity or patent terms
PTA/PTE	Can change the effective expiration date

A crystalline-form patent generally has a 20-year term measured from the earliest effective nonprovisional filing date, subject to patent-term adjustment and other statutory modifications. The original bendamustine patents and product exclusivities do not automatically determine the term of US 8,883,836 [1, 3].

What is the Orange Book status of US 8,883,836?

The Orange Book is the controlling source for determining whether a patent is listed against a specific approved drug product and whether an ANDA applicant must submit a Paragraph IV certification [3].

The relevant regulatory questions are:

Is US 8,883,836 listed against an approved bendamustine injection product?
Is it listed as a drug-substance, drug-product, or method-of-use patent?
Which approved NDA and strength are covered?
Has the listing been removed, delisted or challenged?
Does the asserted patent claim correspond to the proposed ANDA labeling?

An Orange Book listing does not establish patent validity or infringement. It does, however, affect the ANDA review pathway and potential 30-month stay after a Paragraph IV notice and timely infringement action under the Hatch-Waxman Act [4].

Because the claims cover a polymorphic form and a lyophilized injectable composition, the patent is more likely to function as a drug-product or formulation barrier than as a basic active-ingredient patent.

What Paragraph IV challenges and generic launch scenarios exist?

A generic applicant could pursue several design-around strategies:

Form 3 avoidance

The applicant could manufacture a product using a different crystalline form, an amorphous form, or a noncrystalline bendamustine preparation. This approach must account for conversion to Form 3 during manufacturing, storage, reconstitution or administration.

Lyophilization avoidance

A liquid formulation, alternative drying process, or different solid presentation could avoid claims requiring a lyophilized composition. Regulatory feasibility would depend on stability, sterility, concentration, container closure and proposed labeling.

Mannitol avoidance

Claims 13 and 18 create specific mannitol-related exposure. An applicant could investigate alternative bulking agents or excipient systems, although claims 1 and 20 do not necessarily require mannitol if they are practiced using another excipient.

Solvent and cycle avoidance

A different solvent or a materially different lyophilization cycle could avoid claims 15-18 while still requiring analysis of claim 13 and claim 19.

Indication carve-out

Claims 1-3 and 20-22 are limited to listed diseases. An ANDA applicant could consider a section viii labeling carve-out for protected indications, but that strategy would not avoid composition or manufacturing claims. It also would not eliminate risk if the approved label, promotional activity or actual use encouraged a patented indication.

A Paragraph IV certification would create litigation risk if the patent is listed and the NDA holder or patent owner files suit within the statutory period. A Paragraph III certification could delay launch until patent expiration. A Paragraph I or II certification would depend on the Orange Book listing and patent status at the time of filing [4].

How does this patent compare with the broader bendamustine patent estate?

The bendamustine estate can be divided into five categories:

Patent category	Typical coverage	Relationship to US 8,883,836
Active-ingredient patents	Bendamustine molecule and salts	Generally broader chemically, but often earlier-expiring
Polymorph patents	Crystalline Forms 1, 2, 3 or related forms	Directly overlapping technical area
Formulation patents	Injectable solutions, lyophilized cakes, solvents and excipients	Potentially overlapping product coverage
Method-of-use patents	CLL, NHL, Hodgkin's disease or other oncology indications	Overlap with claims 1-3 and 20-22
Manufacturing patents	Crystallization, drying and impurity-control processes	Overlap with claims 13-18

US 8,883,836 is strongest where the commercial product is lyophilized, contains Form 3, and uses the claimed mannitol/organic-solvent process. Its strength is lower against products using another polymorph, a liquid formulation, a different process, or a non-overlapping label.

How strong is the patent estate for bendamustine Form 3?

The estate has several strengths:

The claimed polymorph is defined by objective analytical data.
The claims cover both treatment and manufacturing.
The formulation claims target an injectable presentation.
The process claims can reach manufacturing activity even when the product label is silent on polymorphism.
Dependent claims preserve narrower positions involving mannitol, tert-butanol and the lyophilization cycle.

The principal vulnerabilities are:

Potential enablement and written-description scrutiny for the full breadth of the listed formulations and solvents.
Inherency disputes concerning whether Form 3 forms during lyophilization or storage.
Analytical disputes over the diffraction pattern.
Prior-art challenges based on earlier bendamustine crystallization, freeze-drying or injectable-composition disclosures.
Noninfringement based on a different solid form or process.
Regulatory separation between patented treatment methods and unprotected product characteristics.

Patent strength cannot be assessed from claim text alone. A full validity opinion would require the patent specification, prosecution history, cited references, priority chain, terminal disclaimers, post-grant proceedings and Orange Book records.

What litigation, settlements and licensing issues affect the patent?

The claims indicate a likely Hatch-Waxman dispute profile, but the supplied claim text does not establish a particular Paragraph IV notice, infringement complaint, settlement agreement or license.

For transaction diligence, the critical documents are:

FDA Orange Book patent listings.
USPTO Patent Center prosecution history.
Federal district court complaints and docket entries.
Paragraph IV notice letters.
ANDA settlement agreements submitted under the Medicare Modernization Act.
FTC settlement review materials.
License agreements covering bendamustine injection, Form 3 or branded products.

A license to sell bendamustine injection does not necessarily grant freedom to practice every Form 3 manufacturing claim. Rights should be mapped separately for composition, process, method of treatment, territory, field of use and sublicensing.

Does biosimilar risk apply to bendamustine?

No. Bendamustine hydrochloride is a small-molecule drug, not a biologic. The principal generic pathway is an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act, not a biosimilar application under the Public Health Service Act [4, 5].

Competitive risk therefore comes from:

Paragraph IV ANDA filings.
Paragraph III delayed-launch ANDAs.
Noninfringing formulations.
Compounded or hospital-use alternatives, subject to applicable law.
Additional branded or authorized-generic products.
Pricing pressure after expiration or successful patent challenges.

Key Takeaways

US 8,883,836 is centered on bendamustine hydrochloride Form 3.
The form is defined by required X-ray diffraction reflections at 7.9, 15.5 and 26.1 degrees 2θ within ±0.2 degrees.
Claims 1-12 and 20-22 cover treatment methods using a lyophilized Form 3 composition or injectable preparation.
Claims 13-18 cover production using bendamustine hydrochloride, mannitol, water, an organic solvent and lyophilization.
Claim 17 adds a detailed freeze-drying cycle; claim 18 adds a 15:25.5 bendamustine-to-mannitol ratio.
Claim 19 is a lyophilized composition product-by-process claim.
A generic can target Form 3, lyophilization, mannitol, solvent selection, process conditions or patented indications.
Bendamustine presents generic rather than biosimilar risk.
Orange Book listing and current patent-term data are essential to determine the practical launch barrier.
The patent is commercially strongest against lyophilized injectable products that reproduce the claimed Form 3 profile and manufacturing architecture.

FAQs About US Patent 8,883,836

What bendamustine products are most exposed to US 8,883,836?

Lyophilized injectable products containing bendamustine hydrochloride Form 3, especially products using mannitol and an organic solvent, have the highest exposure.

Can a liquid bendamustine formulation avoid this patent?

A liquid formulation may avoid claims requiring a lyophilized composition, but it must still be evaluated against any separate formulation, method-of-use or active-ingredient patents.

Does using a different polymorph eliminate infringement risk?

It may avoid Form 3 limitations if the product does not contain Form 3. Testing must address polymorphic conversion during manufacturing, storage and reconstitution.

Can a generic omit the protected cancer indications?

A generic may consider a section viii carve-out for patented indications. That strategy does not necessarily avoid composition or manufacturing claims.

Is mannitol required in every claim?

No. Mannitol is central to claim 13 and certain dependent claims, but the treatment claims do not uniformly require mannitol. The specific claim asserted controls.

References

United States Patent and Trademark Office. (2014). U.S. Patent No. 8,883,836, Bendamustine hydrochloride Form 3 and compositions and methods comprising same.
United States Court of Appeals for the Federal Circuit. (2009). Abbott Laboratories v. Sandoz, Inc., 566 F.3d 1282.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application submissions: Hatch-Waxman patent certification provisions.
U.S. Food and Drug Administration. (n.d.). Biosimilar and interchangeable biological products.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Cephalon	TREANDA	bendamustine hydrochloride	POWDER;INTRAVENOUS	022249-002	May 1, 2009	AP	RX	Yes	Yes	8,883,836*PED	⤷ Start Trial			Y		⤷ Start Trial
Cephalon	TREANDA	bendamustine hydrochloride	POWDER;INTRAVENOUS	022249-001	Mar 20, 2008	AP	RX	Yes	Yes	8,883,836*PED	⤷ Start Trial			Y		⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	072777	⤷ Start Trial
Canada	2718939	⤷ Start Trial
Chile	2009000742	⤷ Start Trial
China	101980698	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,883,836

Which drugs does patent 8,883,836 protect, and when does it expire?

Summary for Patent: 8,883,836